Knight Therapeutics partners with Sumitomo Pharma to make key pharmaceuticals available in Canada, so patients have more access to new therapies throughout the country.

Knight Therapeutics is searching for out-of-the-ordinary solutions, has reached agreements with Sumitomo Pharma America Inc. to bring MYFEMBREE, ORGOVYX and vibegron to Canada. Besides, Knight is set to obtain some established pharmaceutical products which are expected to generate annual revenue of C$11.2 million on the fiscal year ending in March 2025.

By the terms of the deal, Knight will be the only company allowed to distribute market, promote and sell these medicines in Canada. There is a C$25.4 million immediate payment and the company might make more payments up to C$15.75 million based on sales targets. In addition, the company expects to buy about C$7 million of goods between now and February.

According to Tsutomu Nakagawa, the move is in line with the company’s plan to focus on important U.S. medications and encourage growth in oncology, regenerative medicine and cell therapy.

Samira Sakhia, President and CEO of Knight Therapeutics, pointed out that the deal adds to their pharmaceutical portfolio in Canada, mainly for women’s health and urology. She sounded hopeful that these novel medical treatments would be made more available to patients and healthcare workers around the nation.

This partnership will help both companies grow their medicines and serve patients in Canada better by offering better healthcare solutions.